{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:02:49Z","timestamp":1791133369666,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Project of Heilongjiang Provincial Health Commission","award":["2020-374"],"award-info":[{"award-number":["2020-374"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03895-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:08:20Z","timestamp":1762520900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"3895_CR1","doi-asserted-by":"publisher","first-page":"114248","DOI":"10.1016\/j.biopha.2023.114248","volume":"159","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yang Y, Li X, et al. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. Biomed Pharmacother. 2023;159:114248. https:\/\/doi.org\/10.1016\/j.biopha.2023.114248.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3895_CR2","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.3747\/co.26.4481","volume":"26","author":"A Sun","year":"2019","unstructured":"Sun A, Durocher-Allen LD, Ellis PM, et al. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Curr Oncol. 2019;26(3):e372\u201384. https:\/\/doi.org\/10.3747\/co.26.4481.","journal-title":"Curr Oncol"},{"key":"3895_CR3","doi-asserted-by":"publisher","unstructured":"D\u00f3mine M, Moran T, Isla D, SCLC). SEOM clinical guidelines for the treatment of small-cell lung cancer ((2019). Clin Transl Oncol. 2020; 22(2):245\u2013255. https:\/\/doi.org\/10.1007\/s12094-020-02295-w","DOI":"10.1007\/s12094-020-02295-w"},{"key":"3895_CR4","doi-asserted-by":"publisher","unstructured":"Amarasena IU, Chatterjee S, Walters JA et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2015; 2015(8):Cd006849. https:\/\/doi.org\/10.1002\/14651858.CD006849.pub3","DOI":"10.1002\/14651858.CD006849.pub3"},{"key":"3895_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/ott.S119714","volume":"10","author":"H Lu","year":"2017","unstructured":"Lu H, Jiang Z. Advances in antiangiogenic treatment of small-cell lung cancer. Onco Targets Ther. 2017;10:353\u20139. https:\/\/doi.org\/10.2147\/ott.S119714.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"3895_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.21037\/tlcr-24-274","volume":"13","author":"Y Du","year":"2024","unstructured":"Du Y, Liu XY, Si XY, et al. Comparative efficacy and safety of anlotinib and Topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study. Transl Lung Cancer Res. 2024;13(7):1518\u201329. https:\/\/doi.org\/10.21037\/tlcr-24-274.","journal-title":"Transl Lung Cancer Res"},{"key":"3895_CR7","doi-asserted-by":"publisher","unstructured":"Yan L, Tongji X, Shouzheng W, et al. Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas. Signal Transduct Target Ther. 2024;9(1). https:\/\/doi.org\/10.1038\/s41392-024-01981-3.","DOI":"10.1038\/s41392-024-01981-3"},{"key":"3895_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene. 2018;654:77\u201386. https:\/\/doi.org\/10.1016\/j.gene.2018.02.026.","journal-title":"Gene"},{"key":"3895_CR9","doi-asserted-by":"publisher","unstructured":"Song P, Wenhong D, Qiangqiang C, et al. Traditional Chinese medicine Brucea Javanica oil enhances the efficacy of anlotinib in a mouse model of Liver-Metastasis of Small-cell lung cancer. Vivo. 2021;35(3). https:\/\/doi.org\/10.21873\/invivo.12395.","DOI":"10.21873\/invivo.12395"},{"issue":"8","key":"3895_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/cam4.2913","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9(8):2621\u201330. https:\/\/doi.org\/10.1002\/cam4.2913.","journal-title":"Cancer Med"},{"issue":"12","key":"3895_CR11","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.21037\/tlcr-24-481","volume":"13","author":"F Tang","year":"2024","unstructured":"Tang F, Zhang J, Xu Z, et al. Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases. Transl Lung Cancer Res. 2024;13(12):3289\u2013302. https:\/\/doi.org\/10.21037\/tlcr-24-481.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"3895_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207\u201319. https:\/\/doi.org\/10.1111\/cas.13536.","journal-title":"Cancer Sci"},{"issue":"7","key":"3895_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng JW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11(7):573. https:\/\/doi.org\/10.1038\/s41419-020-02749-7.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3895_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-022-01256-2","volume":"8","author":"D Han","year":"2022","unstructured":"Han D, Zhang J, Bao Y, et al. Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS\/STING in non-small cell lung cancer. Cell Death Discov. 2022;8(1):468. https:\/\/doi.org\/10.1038\/s41420-022-01256-2.","journal-title":"Cell Death Discov"},{"key":"3895_CR15","doi-asserted-by":"publisher","unstructured":"Yinli Y, Ling L, Zhansheng J, et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 Blockade in lung cancer. Cancer Immunol Immunother. 2020;69(12). https:\/\/doi.org\/10.1007\/s00262-020-02641-5.","DOI":"10.1007\/s00262-020-02641-5"},{"issue":"5","key":"3895_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.21037\/tlcr-22-320","volume":"11","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wang Q, Zhang L, et al. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. Transl Lung Cancer Res. 2022;11(5):776\u201385. https:\/\/doi.org\/10.21037\/tlcr-22-320.","journal-title":"Transl Lung Cancer Res"},{"key":"3895_CR17","doi-asserted-by":"publisher","unstructured":"I M, P R, K E, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung. 2009;187(5). https:\/\/doi.org\/10.1007\/s00408-009-9169-z.","DOI":"10.1007\/s00408-009-9169-z"},{"key":"3895_CR18","doi-asserted-by":"publisher","unstructured":"Ntellas P, Mavroeidis L, Gkoura S, et al. Old Player-New tricks: Non angiogenic effects of the VEGF\/VEGFR pathway in cancer. Cancers (Basel). 2020;12(11). https:\/\/doi.org\/10.3390\/cancers12113145.","DOI":"10.3390\/cancers12113145"},{"key":"3895_CR19","doi-asserted-by":"publisher","unstructured":"Kyle FC, Bonnie SG, Robert CD, et al. A phase I Open-Label study of cediranib plus Etoposide and cisplatin as First-Line therapy for patients with Extensive-Stage Small-Cell lung cancer or metastatic neuroendocrine Non-Small-Cell lung cancer. Clin Lung Cancer. 2024;25(7). https:\/\/doi.org\/10.1016\/j.cllc.2024.08.015.","DOI":"10.1016\/j.cllc.2024.08.015"},{"issue":"3","key":"3895_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jtho.2015.11.001","volume":"11","author":"JK Salama","year":"2016","unstructured":"Salama JK, Gu L, Wang X, et al. Positive interaction between prophylactic cranial irradiation and maintenance Sunitinib for untreated Extensive-Stage small cell lung cancer patients after standard chemotherapy: A secondary analysis of CALGB 30504 (ALLIANCE). J Thorac Oncol. 2016;11(3):361\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2015.11.001.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3895_CR21","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.cllc.2019.12.006","volume":"21","author":"S Senan","year":"2020","unstructured":"Senan S, Okamoto I, Lee GW, et al. Design and rationale for a phase III, Randomized, Placebo-controlled trial of durvalumab with or without Tremelimumab after concurrent chemoradiotherapy for patients with Limited-stage Small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer. 2020;21(2):e84\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2019.12.006.","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"3895_CR22","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.medj.2024.10.004","volume":"5","author":"A Addeo","year":"2024","unstructured":"Addeo A, Liu SV. ADRIATIC: when face value is enough. Med. 2024;5(11):1348\u201350. https:\/\/doi.org\/10.1016\/j.medj.2024.10.004.","journal-title":"Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03895-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:08:20Z","timestamp":1762520900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03895-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3895"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03895-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Medical Ethics Committee of Jiamusi Cancer Hospital and conducted in accordance with the Declaration of Helsinki and China\u2019s Ethical Review Measures for Biomedical Research Involving Human Subjects. All participants provided written informed consent prior to enrollment, acknowledging full understanding of the study objectives, potential risks, and benefits, with the right to withdraw at any time without prejudice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2052"}}